Evidence map›Paper›PMID 40646884›Full record

ArticleAnimals : an open access journal from MDPI2025

A Discrete Choice Experiment to Assess Cat Owners' Preferences for Topical Antiparasitics and the Comparative Ease of Use of a Combined Selamectin and Sarolaner Formulation: An International Survey.

Constantina N Tsokana, George Valiakos, Kennedy Mwacalimba, Danielle Riley, Ashley Enstone, Robin Wyn, Tom Metcalf, Emily Melchior, Eleni Pavlidou, Andrea Wright

Abstract read
In one paragraph

Article in Animals : an open access journal from MDPI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Constantina N TsokanaLaboratory of Parasitology and Parasitic Diseases, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0003-4180-6310
George ValiakosLaboratory of Microbiology and Parasitology, Faculty of Veterinary Science, University of Thessaly, 43100 Karditsa, Greece.ORCID 0000-0002-3869-5026
Kennedy MwacalimbaIn-Market Clinical Studies and Outcomes Research, Global Medical Affairs, Zoetis, Parsippany, NJ 07054, USA.
Danielle RileyAdelphi Values, PROVE, Adelphi Mill, Bollington SK10 5JB, Cheshire, UK.
Ashley EnstoneAdelphi Values, PROVE, Adelphi Mill, Bollington SK10 5JB, Cheshire, UK.
Robin WynAdelphi Values, PROVE, Adelphi Mill, Bollington SK10 5JB, Cheshire, UK.
Tom MetcalfAdelphi Values, PROVE, Adelphi Mill, Bollington SK10 5JB, Cheshire, UK.
Emily MelchiorIn-Market Clinical Studies and Outcomes Research, Global Medical Affairs, Zoetis, Parsippany, NJ 07054, USA.
Eleni PavlidouAsclepius One Health Platform, 10671 Athens, Greece.
Andrea WrightIn-Market Clinical Studies and Outcomes Research, Global Medical Affairs, Zoetis, Parsippany, NJ 07054, USA.ORCID 0000-0002-1903-1814

Funding

Zoetis (United States) N/A
6 · The paper itself

Abstract

Cat owners are involved in their cats' healthcare, including the prevention of parasitic diseases. However, a comprehensive understanding of their preferences for feline antiparasitics is lacking. This study addresses this gap through a multifaceted methodology comprising three phases. In Phase 1, the physical properties and usability aspects of seven topical antiparasitic formulations were assessed. Within Phase 2, an ease-of-use study was conducted to evaluate the cat owners' application experience with deidentified products representing three topical antiparasitics. Phase 3 included the identification and validation of product attributes most valued by pet owners through interviews with cat owners and veterinary experts. The product attributes identified informed the subsequent quantitative discrete choice experiment (DCE), which involved 1040 cat owners from different countries (Australia/New Zealand, Canada, Greece/Spain, and the UK) and aimed to analyze their preferences based on choices among product profiles mirroring four topical antiparasitics: selamectin-sarolaner, moxidectin-fluralaner, moxidectin-imidacloprid, and eprinomectin-esafoxolaner-praziquantel. Phase 1 showed that the selamectin-sarolaner formulation exhibits minimal odor, less stickiness, and less drying time. The ease-of-use study (Phase 2) showed that the blinded product representing the selamectin-sarolaner formulation was characterized by seamless application, rapid dispensing, and a sense of control during application. The quantitative DCE study (Phase 3) indicated a preference for the product profile mirroring the selamectin-sarolaner formulation among a global sample of cat owners. Demographic characteristics such as gender, age, and insurance status influenced their preferences. Key predictors for preferring the selamectin-sarolaner formulation over at least one comparator treatment included the ability to confirm successful administration, age restrictions, ease of application, and the time before the cat could sit on furniture following administration. These findings suggest that cat owners prioritize ease of use, safety, and overall user experience, providing valuable guidance for veterinary practitioners to make informed treatment recommendations.

Indexed as

antiparasiticscatsdiscrete choice experimentease of usepet ownersphysical propertiespreferences

Identifiers

PMID40646884
PMCPMC12248694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.